Manifest Technologies Emerges From Stealth With Strategic Investors and Prepares for Next Development Stage of AI-Powered Precision Neuroscience
28 March 2024 - 3:22PM
Business Wire
- Company Funded by Kaleida Capital, Atma Capital, Connecticut
Innovations and angel investors
- NAIO™ (Neuroscience and Artificial
Intelligence Optimized) technology platform, building
on 10 years’ and over $50 million NIH-funded research at Yale
University School of Medicine
- Leadership Team, with an extensive track record and deep
expertise in brain computational imaging, commercialization, and
partnerships
- Manifest recently signed a multi-year agreement with a top-five
pharmaceutical firm, providing them early access to its biomarker
validation technology for a high priority neurological
indication
Manifest Technologies, Inc., developer of an AI-powered
computational neuro-imaging platform for CNS disease, today
unveiled the company after completing its initial funding and
partnership with a top five global pharmaceutical company.
Today, over one billion people on the planet suffer from some
form of a brain disorder, with an estimated economic burden of as
much as $8.5 trillion per year. There is an urgent unmet need for
more rapid and precise development of treatments that are
ultimately delivered to the right person at the right time. Recent
acquisitions in the neuroscience space highlight the need for tools
that can optimize clinical trials and drive more efficient drug
development based on precise neural targets.
Manifest was founded in 2021 by a group of leaders in
computational psychiatry at Yale University School of Medicine to
transform how CNS treatments are developed and ultimately delivered
in the clinic. Supported by over $50 million of NIH-funded research
at Yale, the scientific founders pioneered the NAIO™ technology
with the goal of leveraging computational neuroscience and AI to
enable a true precision medicine approach to mental illness and
neurodegenerative diseases like Alzheimer’s Disease and Parkinson’s
Disease.
Specifically, the NAIO™ platform enables CNS pharmaceutical
companies to use human neuroimaging to unlock quantitative
indication and patient selection decisions for clinical trials,
saving billions of dollars in clinical development. Manifest is
actively working with Johnson & Johnson to deploy its solutions
across several programs.
“With a group of key initial investors and strategic partners we
believe Manifest is ideally positioned to advance a platform that
unifies computational clinical neuroscience with AI technology to
guide the discovery and delivery of personalized treatments that
are most likely to benefit patients at the individual level,” said
Manifest Technologies Founding CEO and Associate Professor of
Psychiatry & Neuroscience at Yale University, Alan
Anticevic.
“We are thrilled to support Manifest’s efforts to quantitatively
map the complexities of psychiatric disease. We recognize the
tremendous potential of the NAIO platform to accelerate CNS
clinical development and look forward to contributing to a future
where tailored, individualized patient care is standard,” said
Ariane Tom, Managing Partner at Kaleida Capital.
In addition to Dr. Anticevic, the Manifest Board of Directors
includes former CMO of Biohaven Pharmaceuticals, Robert Berman, and
Co-Founder and Associate Professor of Psychological & Brain
Sciences at Dartmouth College, John Murray.
About Manifest Technologies
Manifest Technologies is transforming CNS health through
AI-powered precision neuroscience and computational neuroimaging.
Manifest was founded in 2021 by a group of leading scientists who
have created the NAIO™ (Neuroscience and Artificial
Intelligence Optimized) platform. NAIO™ incorporates
proprietary software and several patents under an exclusive license
from Yale University. Manifest is building a suite of specific
applications out of the NAIO™ platform to meet the needs of both
pharmaceutical CNS R&D and health care providers.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240328700688/en/
press@manifesttech.io